Biocytogen’s YH008 Greater China Licensee Chipscreen NewWay Announces First-Patient-In for Bispecific Antibody NWY001, a Next-Gen Tumor Immunotherapy
Beijing, China, January 5, 2024 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) partner Chipscreen NewWay Biosciences (“Chipscreen NewWay”) achieved first-patient-in for a phase…
Read more
Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma
BEIJING, China and BOSTON, Massachusetts, USA---Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen,” HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics,…
Read more
Manhattan BioSolutions Enters into Evaluation and Potential Licensing Agreement with Biocytogen for Use of Innovative Antibodies in Targeted Therapies
New York City, New York and Beijing, China, January 3, 2023 – Manhattan BioSolutions, Inc. (Manhattan Bio or MABS), an emerging biotech company developing innovative…
Read more
Biocytogen BDL and Leadership Team to Participate in the 42nd Annual JPM Healthcare Conference and its Satellite Conferences
Biocytogen (HKEX: 02315) will attend the upcoming 42nd J.P. Morgan (JPM) Healthcare Conference and several satellite conferences, which will be held in San Francisco from…
Read more
Biocytogen and CtM Bio Achieve Milestone Progress in Co-Developing a TCR-mimic Antibody-based Multi-Specific T Cell Engager Targeting WT1/HLA-A02
Beijing, China and Shanghai, China, December 27, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and CtM Biotech (Shanghai) Co., Ltd ("CtM Bio")…
Read more
Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences
Beijing, China and San Diego, US, December 19, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd (“Biocytogen”, HKEX: 02315) today announced that it has entered into…
Read more
Webinar: Maximize Your Drug Design Possibilities with RenNano-derived Fully Human Nanobodies
Our webinar “Maximize Your Drug Design Possibilities with RenNano-derived Fully Human Nanobodies" was live at 11AM EST on January 24, 2024. About the webinar:…
Read more
Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop Antibody-Drug Conjugates Targeting Solid Tumors
Beijing, China and Barcelona, Spain, December 18, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery…
Read more
Join us at Antibody engineering and Therapeutics 2023: Dec 13-16
Join us at Antibody engineering and Therapeutics 2023 in San Diego, CA from December 13-16! Meet us at Booth 208, and at our 3 posters,…
Read more
Biocytogen Secures U.S. Patent for Key Technology of the Fully Human Antibody Mouse (RenMab) Platform
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) is pleased to announce that the company has been granted a patent from the United States Patent…
Read more